An Emergency Medicine Broadsheet
·Phoenix·
Est. MMXXVI
Blue Fish Med · Today's Topic
Pediatric Oncologic Emergencies - Complications of Known Malignancy
Neutropenic children may deteriorate quickly, and fever can be the only early sign of life-threatening infection. Missed tumor lysis, leukostasis, or spinal cord compression can also cause irreversible harm.
Also known aspediatric cancer emergencies · childhood cancer complications · tumor lysis syndrome · febrile neutropenia · malignant spinal cord compression · hyperleukocytosis
By the Blue Fish Med DeskOct 9, 2026 · Phoenix
0:00 / –:––AI‑generated audio
A 9-year-old halfway through chemotherapy sits curled beneath a thin blanket, cheeks flushed and lips cracked. The parent says the fever began an hour ago; the child reports mouth sores and has not eaten since yesterday. The infusion-center paperwork lists a recent low neutrophil count, but there is no central-line redness and the child is still answering questions. The first antibiotic has not yet been chosen.
— What’s your move? Read on.
Before you read
Which findings justify adding gram-positive coverage?
What complications besides infection must you actively screen for?
When to Think of It
Fever in a child receiving cytotoxic therapy—commonly defined as a single temperature ≥38.3°C or ≥38.0°C sustained for an hour—with known or possible neutropenia is an emergency. Also look for mucositis, line infection, hypotension, respiratory or neurologic symptoms, new weakness or back pain, and laboratory evidence of tumor lysis (rising potassium, phosphate, uric acid, or creatinine; falling calcium).
Sick or Not Sick
The key fork is stable versus septic/unstable, not how impressive the fever looks. Shock, altered mental status, respiratory distress, poor perfusion, or suspected leukostasis demands immediate resuscitation and escalation while antibiotics are prepared.
The First Fifteen Minutes
Obtain cultures from each central-line lumen and a peripheral site if feasible, CBC, chemistry, renal function, lactate if ill, and tumor-lysis labs—but do not delay antibiotics.
Fever with known/suspected neutropenia: cefepime 50 mg/kg IV (maximum 2 g/dose) every 8 hours; it covers common dangerous gram-negative pathogens, including Pseudomonas. Give promptly, ideally within 60 minutes.
Shock, prior resistant gram-negative infection, or local protocol indicating broader coverage: meropenem 20 mg/kg IV (maximum 1 g/dose) every 8 hours; it broadens coverage when cefepime may be inadequate. Confirm higher doses for selected indications with institutional guidance.
Add suspected catheter infection, skin/soft-tissue infection, pneumonia, hemodynamic instability, or known resistant gram-positive infection: vancomycin 15 mg/kg IV every 6 hours, adjusted with pharmacy monitoring; it adds resistant gram-positive coverage when these features raise that risk. Do not add routinely for fever alone.
Poor perfusion or shock: isotonic crystalloid 10 mL/kg IV, then reassess perfusion and lungs before repeating; this restores intravascular volume while limiting fluid overload.
Treat airway, breathing, and circulation problems in parallel; involve pediatric oncology early.
Definitive Care & Disposition
Admit febrile neutropenic children for oncology-directed management; ICU care is appropriate for shock, respiratory failure, altered mental status, or rapidly worsening laboratory abnormalities. Reassess cultures and antibiotics with oncology/infectious disease. Screen for concurrent tumor lysis, leukostasis, bleeding/coagulopathy, and spinal cord compression; urgent imaging and specialist-directed intervention may be needed for focal neurologic deficits or back pain.
How This One Kills
The dangerous failure is waiting for an ANC, culture, or a “sicker-looking” child before giving antipseudomonal antibiotics. Neutropenia can blunt local inflammatory signs, and deterioration may be abrupt.
The Differential — What Else Looks Like This
Viral illness — mild appearance does not exclude bacteremia in neutropenia; false reassurance delays antibiotics.
Central-line infection — line-site redness may be absent; missing it can leave the source uncontrolled.
Tumor lysis syndrome — electrolyte and renal abnormalities, often after therapy or with bulky disease, point away from isolated infection; missing it risks arrhythmia or seizure.
Leukostasis — respiratory or neurologic dysfunction with very high leukocyte burden; confusing it with uncomplicated fever delays urgent oncology-directed care.
The Second-Day Story
A child may be afebrile after antipyretics, present only with lethargy or poor feeding, or have no focal infection despite bacteremia. Older children may minimize symptoms, and steroids or neutropenia can erase expected inflammatory findings. Use the treatment timeline, recent counts, vital signs, and caregiver report—not a reassuring examination alone—to set the threshold for cultures and antibiotics.
Back to Our Patient
Back to our 9-year-old with cracked lips and a new fever: chemotherapy plus a recent low neutrophil count makes febrile neutropenia the working emergency, even though the child is still answering questions and the line looks normal. First, stratify for instability; the child is currently perfusing adequately without respiratory distress or altered mental status. Obtain cultures and urgent labs, then give cefepime promptly; add vancomycin only if a qualifying trigger emerges. Admit for oncology-directed monitoring and assess in parallel for infection, tumor lysis, and other treatment complications.
Patient Presentation to Attending
How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling
“This is a 9-year-old receiving chemotherapy who presents with fever to 38.4°C and one day of poor intake and painful oral sores. The parent reports a recent low neutrophil count; there is no cough, dyspnea, focal abdominal pain, or redness or drainage at the central line. The child is alert, with warm extremities, brisk capillary refill, and no respiratory distress or focal neurologic deficit. Mucositis is present, but there is no clear bacterial source. I’m concerned for febrile neutropenia with risk of rapid progression, though the child is currently hemodynamically stable. I’ll obtain central and peripheral cultures and urgent CBC, chemistry, renal function, and tumor-lysis labs, then give IV cefepime without waiting for the ANC. I’ll discuss with pediatric oncology and admit, escalating coverage or level of care if instability or a specific indication develops.”
Study Directive
From memory, list the clinical triggers for empiric vancomycin in febrile neutropenia.
Rehearse a first-15-minute order set: cultures, labs, antibiotic choice, and instability reassessment.
Review tumor-lysis labs and practice identifying the dangerous direction of change in potassium, phosphate, calcium, uric acid, and creatinine.
Prusakowski MK, Cannone D · Hematol Oncol Clin North Am, 2017 · PMID 29078932 · cited 16×
A broad reference for recognizing and stabilizing life-threatening complications in children with known cancer, including febrile neutropenia, tumor lysis syndrome, and oncologic compression syndromes.
More in Today's Issue
3 additional topics
2 of 4
Pediatric Oncologic Emergencies - New Diagnosis
A first cancer presentation may arrive as bleeding, infection, respiratory distress, neurologic dysfunction, or electrolyte derangement. Early stabilization...
Also known asnew-onset pediatric cancer · childhood cancer diagnosis · pediatric malignancy · newly diagnosed cancer
0:00 / –:––AI‑generated audio
The Case
A 6-year-old is brought in after a week of unusual fatigue; today, a parent noticed bruises along both shins and a pinpoint rash across the shoulders. The child’s face looks pale under the fluorescent lights, and the spleen is palpable below the left ribs. A blood count is pending, while the family watches the monitor and waits for the next result.
Before You Read
Which findings make a new blood cancer an urgent possibility?
What must you assess before deciding how to handle a very high white-cell count?
Which common interventions can worsen early complications?
Why It Matters
A first cancer presentation may arrive as bleeding, infection, respiratory distress, neurologic dysfunction, or electrolyte derangement. Early stabilization and oncology involvement matter—but some well-intended interventions can increase risk.
When to Think of It
Think new leukemia or another malignancy with unexplained pallor, bruising or petechiae, bone pain, persistent fever, lymphadenopathy, hepatosplenomegaly, or cytopenias. Look urgently for hyperleukocytosis with respiratory or neurologic symptoms, tumor lysis, major bleeding, sepsis, and mediastinal mass effects.
Sick or Not Sick
The key call is stable without end-organ symptoms versus unstable or symptomatic from hyperleukocytosis, bleeding, infection, or mass effect. A very high white count alone does not diagnose leukostasis; respiratory or neurologic compromise makes it an emergency requiring immediate oncology-led management.
The First Fifteen Minutes
Place on monitoring; obtain CBC with differential and smear, metabolic panel, uric acid, phosphate, calcium, LDH, coagulation studies, type and screen, and blood cultures if febrile or ill. Contact pediatric oncology early.
Suspected tumor lysis risk (high tumor burden, very high cell count, or biochemical abnormalities): start isotonic IV fluid at about 1.5–2 times maintenance, tailored to cardiac/renal status and urine output; avoid potassium and phosphate in fluids. This supports renal clearance of released solutes.
Tumor-lysis risk without established hyperuricemia or high-risk features: allopurinol 10 mg/kg/day PO divided every 8 hours (maximum 800 mg/day); it prevents formation of new uric acid but does not clear existing uric acid.
Established hyperuricemia or high-risk tumor lysis: rasburicase 0.15–0.2 mg/kg IV once; it rapidly degrades uric acid. Check G6PD risk first when feasible; it is contraindicated in G6PD deficiency.
Fever with suspected neutropenia: cefepime 50 mg/kg IV (maximum 2 g/dose) every 8 hours, given promptly; it covers serious gram-negative infection while evaluation continues.
Shock: isotonic crystalloid 10 mL/kg IV, reassessing after each bolus; avoid indiscriminate large-volume boluses if cardiac/renal compromise or mediastinal obstruction is suspected.
Avoid empiric steroids before oncology discussion when feasible; they can rapidly alter diagnostic tissue and complicate definitive classification. Do not transfuse red cells reflexively when hyperleukocytosis is suspected.
Definitive Care & Disposition
Admit for urgent pediatric oncology evaluation; ICU care is appropriate for shock, respiratory compromise, neurologic symptoms, serious electrolyte disturbance, or high-risk tumor lysis. Oncology directs diagnostic testing and treatment, including marrow evaluation and management of hyperleukocytosis. Transfusions and cytoreductive interventions should be coordinated with oncology; red-cell transfusion can increase viscosity, while platelet support may be needed for significant bleeding or procedures.
How This One Kills
The failure to fear is iatrogenic viscosity: reflexive red-cell transfusion in a patient with marked hyperleukocytosis may worsen leukostasis. Stabilize life threats, but coordinate transfusion and cytoreduction with oncology.
The Atypical Presentation
The textbook child with bruising, bone pain, and obvious organ enlargement may instead present only with fatigue, limp, recurrent “viral” symptoms, or an incidental abnormal blood count. Early disease may have few blasts on a peripheral smear, and fever may be absent. Persistent symptoms, more than one abnormal cell line, or unexplained hepatosplenomegaly should prompt repeat blood-count review and specialist discussion rather than reassurance from a single initial impression.
Back to Our Patient
Back to our 6-year-old with new bruises, petechiae, pallor, and a palpable spleen: the presentation raises concern for a new hematologic malignancy, but the first decisions are driven by stability and end-organ effects. The child is currently alert and without respiratory distress or active major bleeding, so obtain the urgent blood count, smear, chemistry, tumor-lysis labs, and coagulation studies while contacting pediatric oncology. If the results show high tumor-lysis risk, begin carefully monitored fluids and the appropriate uric-acid-lowering strategy; if fever with possible neutropenia is present, give cefepime promptly. Avoid reflex red-cell transfusion or pre-diagnostic steroids, and admit for urgent oncology-led evaluation.
Patient Presentation to Attending
“This is a 6-year-old with one week of fatigue and new bruising and petechiae, with no known malignancy. The parent reports no trauma or active bleeding; there is no respiratory distress, altered mental status, or focal neurologic deficit. Exam shows pallor, scattered petechiae, and a palpable spleen. I’m concerned for a new hematologic malignancy with possible cytopenias and tumor-lysis risk; the child is currently stable. I’ll obtain a CBC with smear, metabolic and tumor-lysis labs, coagulation studies, and type and screen, and contact pediatric oncology now. I’ll avoid reflex red-cell transfusion and steroids while assessing for hyperleukocytosis, infection, bleeding, and electrolyte abnormalities. The child needs admission for urgent specialist evaluation.”
Study Directive
Draw the tumor-lysis pattern from memory, including which direction potassium, phosphate, calcium, uric acid, and creatinine move.
Practice a two-minute oral handoff for suspected new leukemia that explicitly states stability, leukostasis symptoms, and tumor-lysis risk.
Review your institution’s pediatric hyperleukocytosis and transfusion protocols.
Key Medications
Allopurinol 10 mg/kg/day PO divided every 8 hours; maximum 800 mg/day; renal adjustment may be required.
Rasburicase 0.15–0.2 mg/kg IV once; repeat dosing is specialist- and protocol-directed. Check G6PD status when feasible; contraindicated in G6PD deficiency.
Cefepime for febrile neutropenia: 50 mg/kg IV every 8 hours; maximum 2 g/dose, with renal adjustment.
Verify pediatric dosing and tumor-lysis protocols with institutional guidance.
High-Yield Pearls
A peripheral smear without obvious blasts does not exclude leukemia when cytopenias, organomegaly, or persistent symptoms are unexplained.
In suspected hyperleukocytosis, avoid interventions that increase viscosity unless a clear indication is coordinated with oncology.
The Mimics
Immune thrombocytopenia — isolated thrombocytopenia without anemia, neutropenia, or organomegaly; missing marrow disease delays urgent diagnosis.
Aplastic anemia — pancytopenia without the same pattern of circulating blasts or organomegaly; mislabeling it can misdirect diagnostic workup.
Viral marrow suppression — a compatible acute illness and transient cytopenias may fit, but persistent abnormalities or blasts demand urgent evaluation; false reassurance delays diagnosis.
Sepsis-associated coagulopathy — shock and abnormal coagulation can resemble malignancy-related illness; missing sepsis delays time-critical antimicrobial therapy.
Board Question
A child with newly suspected leukemia has a markedly elevated white-cell count but is alert, breathing comfortably, and hemodynamically stable. Which action is most appropriate?
ATransfuse packed red cells to improve fatigue immediately
BGive empiric corticosteroids before diagnostic evaluation
CContact pediatric oncology urgently and assess for tumor lysis and evolving end-organ symptoms
DDischarge if the child has no respiratory symptoms
Reveal answer
Correct: C
A high white-cell count requires urgent specialist evaluation and monitoring for tumor lysis and leukostasis, but the count alone does not establish leukostasis. Reflex red-cell transfusion or steroids can complicate management and diagnostic evaluation.
For a child with suspected new cancer, recognize and stabilize time-critical complications such as tumor lysis syndrome, hyperleukocytosis, and mediastinal mass before definitive oncologic treatment.
3 of 4
SVC Syndrome and Thoracic Central Venous Obstruction
Thoracic central venous obstruction can progress to airway compromise or cerebral edema, but many patients are initially stable. Treatment depends on...
Also known assuperior vena cava syndrome · SVCS · SVC obstruction · mediastinal mass · vena cava obstruction
0:00 / –:––AI‑generated audio
The Case
A 58-year-old arrives with a puffy face, tight shirt collar, and breathlessness that worsens when lying flat. The veins across the upper chest stand out beneath the skin, and the voice sounds rougher than it did last month. The patient grips the bedrail rather than recline as the next assessment begins.
Before You Read
Which bedside feature makes this immediately life-threatening?
What imaging best identifies the level and cause of obstruction?
When is anticoagulation appropriate—and when is it not?
Why It Matters
Thoracic central venous obstruction can progress to airway compromise or cerebral edema, but many patients are initially stable. Treatment depends on distinguishing external compression from intraluminal thrombosis.
When to Think of It
Facial, neck, or upper-extremity swelling; distended neck or chest-wall veins; dyspnea, cough, hoarseness, headache, or symptoms worse when supine suggest impaired upper-body venous return. Consider mediastinal malignancy, catheter-associated thrombosis, and other compressive or thrombotic causes.
Sick or Not Sick
The critical fork is threatened airway or cerebral perfusion versus stable obstruction. Stridor, rapidly worsening respiratory distress, confusion, syncope, or severe headache warrants immediate airway/critical-care and specialist involvement.
The First Fifteen Minutes
Sit the patient upright; monitor, assess airway and work of breathing, establish access, and provide oxygen if hypoxemic.
Obtain urgent contrast-enhanced CT of the chest if the patient is stable enough; it can show the obstruction, thrombus, collateral veins, and a possible mass. If unstable, stabilize first and coordinate imaging with the resuscitation team.
Confirmed or strongly suspected acute thrombotic obstruction, with no major bleeding contraindication: unfractionated heparin 80 units/kg IV bolus (maximum 10,000 units), then 18 units/kg/hour IV infusion, titrated by institutional aPTT or anti-Xa protocol; it limits thrombus extension and is rapidly titratable. Omit or modify the bolus when bleeding risk or an imminent procedure warrants.
Do not give anticoagulation solely for external compression, and do not use steroids or diuretics routinely; they do not reliably relieve the obstruction and may complicate diagnosis.
Definitive Care & Disposition
Admit patients with significant symptoms, airway or neurologic concerns, or an identified acute thrombosis. Involve interventional radiology/vascular specialists and oncology as indicated. Endovascular stenting can rapidly relieve severe symptomatic obstruction; catheter-directed intervention or thrombectomy is selected case by case. If a mass is suspected, arrange tissue diagnosis and cause-directed treatment; anticoagulation is for coexisting thrombosis, not the compression itself.
How This One Kills
The failure mode is treating every patient as though they have a clot—or every patient as though they have a tumor. Anticoagulating external compression adds bleeding risk without relieving the obstruction; delaying airway planning in a deteriorating patient risks losing control of a difficult airway.
The Atypical Presentation
Obstruction may develop gradually, so collateral veins form and symptoms can be limited to morning facial fullness, cough, headache, or difficulty bending forward. Older adults may describe only reduced exercise tolerance, and a pre-existing catheter can make thrombosis plausible even without dramatic swelling. Compare with prior symptoms and examine the neck, arms, and chest for venous collaterals; do not let a relatively comfortable appearance dismiss progressive symptoms.
Back to Our Patient
Back to our 58-year-old with a tight collar, visible chest-wall veins, and breathlessness when supine: the pattern suggests thoracic central venous obstruction. First determine whether the airway or cerebral function is threatened; the patient is uncomfortable but speaking in full sentences without stridor or confusion. Keep the patient upright, monitor closely, and obtain urgent contrast CT to distinguish thrombus from external compression. Start heparin only if acute thrombosis is confirmed or strongly suspected and bleeding risk is acceptable; admit for specialist-directed treatment and escalate immediately if respiratory or neurologic status worsens.
Patient Presentation to Attending
“This is a 58-year-old with progressive facial fullness and positional dyspnea, now with visible neck and upper-chest veins. The patient reports no abrupt chest or back pain and has no syncope, confusion, or tongue swelling. Exam shows facial and upper-chest venous engorgement; the patient is speaking comfortably without stridor or hypoxemia. I’m concerned for thoracic central venous obstruction, with airway compromise not currently evident. I’ll keep the patient upright, monitor closely, and obtain urgent contrast CT to identify thrombus versus external compression. I’ll involve the appropriate specialists and start unfractionated heparin only if a thrombotic cause is identified or strongly suspected and there is no contraindication. The patient needs admission for definitive evaluation and treatment.”
Study Directive
Sketch the clinical decision fork: airway/cerebral threat, thrombus, or external compression.
Review CT findings that distinguish intraluminal thrombus from a compressive mediastinal process.
Rehearse a bedside airway-risk handoff for a patient who cannot tolerate lying flat.
Key Medications
Unfractionated heparin for acute thrombosis: 80 units/kg IV bolus (maximum 10,000 units), then 18 units/kg/hour IV, titrated to institutional protocol; dosing varies by indication and bleeding risk.
Chest-wall collateral veins favor a gradual process; their presence can explain why striking imaging findings coexist with modest symptoms.
Ask whether symptoms worsen supine or with bending forward—positional worsening can reveal limited venous return before overt respiratory distress.
The Mimics
Angioedema — abrupt lip or tongue swelling without chronic chest-wall collaterals; confusing it with venous obstruction may delay airway-directed care.
Heart failure — generalized edema and pulmonary congestion rather than isolated upper-body venous engorgement; missing it misdirects imaging and intervention.
Pulmonary embolism — acute hypoxemia, pleuritic pain, or right-heart strain without the characteristic chronic upper-body collateral pattern; missing it delays a separate time-critical diagnosis.
Thoracic aortic pathology — abrupt chest/back pain or pulse deficit; attributing it to venous congestion can miss a catastrophic vascular emergency.
Board Question
A stable patient has facial swelling, chest-wall venous collaterals, and a mediastinal mass compressing the superior vena cava on CT, without intraluminal thrombus. What is the best next step?
ABegin therapeutic anticoagulation for all cases of venous obstruction
BArrange cause-directed specialist care; anticoagulation is not indicated for compression alone
CGive routine high-dose steroids and discharge
DPerform immediate thrombolysis
Reveal answer
Correct: B
External compression and intraluminal thrombosis require different treatment. Anticoagulation is not indicated for compression alone; severe symptoms may require endovascular intervention and cause-directed treatment.
Understanding the anatomy and endovascular treatment options for thoracic central venous obstruction helps guide imaging and urgent specialist consultation when a patient presents with SVC syndrome.
4 of 4
DOACs and Kidney Disease
Renal dysfunction can increase exposure to some direct oral anticoagulants, especially during acute kidney injury, but the degree varies by drug. Delayed...
Also known asdirect oral anticoagulants · DOAC · NOAC · renal impairment · chronic kidney disease · renal failure
A 74-year-old with advanced kidney disease arrives pale and clammy, holding a basin after several episodes of dark vomit. The medication list shows apixaban, but the family is unsure whether the morning dose was taken. The blood pressure is falling, and the last creatinine result is from a clinic visit two months ago.
Before You Read
Which renal-function estimate should guide DOAC dosing?
Does kidney disease alone justify reversal?
What is the immediate reversal strategy for life-threatening bleeding?
Why It Matters
Renal dysfunction can increase exposure to some direct oral anticoagulants, especially during acute kidney injury, but the degree varies by drug. Delayed recognition of major bleeding—or reflex reversal without weighing thrombosis risk—can cause harm.
When to Think of It
Check the anticoagulant, indication, dose, last known dose, interacting medications, bleeding severity, and current renal function. Use Cockcroft–Gault creatinine clearance (CrCl) for most labeled DOAC dosing decisions; eGFR alone may mislead, especially in older adults or changing kidney function.
Sick or Not Sick
The key fork is life-threatening/critical-site bleeding versus no major bleeding. Kidney disease or an elevated creatinine alone does not mandate holding or reversing a DOAC; ongoing major bleeding, hemodynamic instability, or critical-site hemorrhage drives emergency reversal decisions.
The First Fifteen Minutes
Stabilize airway, breathing, and circulation; establish IV access, send CBC, metabolic panel, type and cross, and assess renal function and the last dose. A normal PT/INR does not reliably exclude clinically important DOAC effect.
Life-threatening or uncontrolled bleeding with recent dabigatran use: idarucizumab 5 g IV (two 2.5-g doses); it binds dabigatran directly. Consider a second 5-g dose only for persistent/recurrent clinically relevant bleeding with specialist guidance.
Life-threatening or uncontrolled bleeding with apixaban/rivaroxaban effect and appropriate indication: andexanet alfa, selected by agent, dose, and timing: low dose 400 mg IV bolus, then 4 mg/min IV for 120 minutes, or high dose 800 mg IV bolus, then 8 mg/min IV for 120 minutes. Verify the dose-selection criteria and local protocol; it reverses factor Xa inhibitor activity but carries thrombotic risk.
If andexanet is unavailable or unsuitable for major factor Xa inhibitor bleeding: 4-factor PCC 50 units/kg IV (maximum 5,000 units) per institutional protocol; it supports thrombin generation, but does not remove the drug. Reversal options and preferred dosing vary by institution—consult pharmacy/hematology.
Very recent ingestion (generally within 2–4 hours) with protected airway: activated charcoal 50 g PO once may reduce absorption; do not give if aspiration risk is unacceptable.
Definitive Care & Disposition
Admit major bleeding for ongoing monitoring, source control, and reassessment of renal function and anticoagulant effect. Dabigatran is dialyzable; factor Xa inhibitors are not meaningfully removed by hemodialysis. After bleeding control, reassess the indication, renal trajectory, and timing for restarting anticoagulation. For stable patients without major bleeding, base hold/continue decisions on the drug, CrCl trend, dose, indication, and thrombotic risk—not kidney disease alone.
How This One Kills
Do not trust a “normal INR” to rule out clinically important apixaban or rivaroxaban effect. Equally dangerous is reversing an anticoagulant solely because creatinine is high, without assessing active bleeding and thrombosis risk.
The Atypical Presentation
Older adults with chronic kidney disease may present with weakness, a fall, confusion, or a subtle hemoglobin decline rather than obvious bleeding. Acute kidney injury can change drug exposure over days, while a stale baseline creatinine or reassuring INR obscures the risk. Establish the medication and last-dose history from a caregiver or pharmacy when possible, compare current kidney function with baseline, and search actively for occult bleeding.
Back to Our Patient
Back to our 74-year-old with advanced kidney disease, dark vomit, and falling blood pressure: this is suspected life-threatening upper GI bleeding in a patient taking apixaban, not a creatinine-driven indication for reversal. Stabilize, establish the last dose if possible, send blood work and type and cross, and assess current renal function while arranging urgent source control. If significant apixaban effect is likely and bleeding remains life-threatening, use andexanet alfa according to dose and timing criteria, or 4-factor PCC per local protocol if andexanet is unavailable or unsuitable. Admit for resuscitation, definitive bleeding management, and reassessment of the anticoagulation plan.
Patient Presentation to Attending
“This is a 74-year-old with advanced kidney disease on apixaban who presents after several episodes of dark emesis with worsening weakness. The family is unsure whether the morning dose was taken, and the most recent creatinine available is two months old. The patient is pale and clammy with falling blood pressure; there is no reported trauma or focal neurologic deficit. I’m concerned for life-threatening upper GI bleeding with potentially prolonged anticoagulant effect in the setting of renal dysfunction. I’ll resuscitate, obtain CBC, metabolic panel, type and cross, and clarify the last dose while arranging urgent GI evaluation and source control. If significant apixaban effect is likely and bleeding remains uncontrolled, I’ll give andexanet using the dose dictated by last-dose timing, or 4-factor PCC per protocol if it is unavailable or unsuitable. The patient requires admission and close reassessment of renal function, bleeding, and thrombosis risk.”
Study Directive
From memory, state the difference between eGFR and Cockcroft–Gault CrCl for DOAC dosing.
Build a one-page reference for the four commonly used DOACs: renal clearance, key renal thresholds, reversal agent, and dialysis removability.
Review your hospital’s andexanet and PCC protocols, then practice choosing a strategy for a major bleed with an uncertain last dose.
Key Medications
Idarucizumab: 5 g IV for life-threatening/uncontrolled dabigatran bleeding.
Andexanet alfa: low dose 400 mg IV bolus then 4 mg/min for 120 minutes; high dose 800 mg IV bolus then 8 mg/min for 120 minutes. Selection depends on agent, dose, and time since last dose; verify the current institutional protocol.
4-factor PCC:50 units/kg IV, maximum 5,000 units, commonly used for major factor Xa inhibitor bleeding when andexanet is unavailable or unsuitable; institutional protocols vary.
Activated charcoal:50 g PO once for selected recent ingestion with a protected airway.
Adult DOAC dosing should use CrCl and is indication-specific. Apixaban dosing for atrial fibrillation is reduced to 2.5 mg PO twice daily when at least two apply: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL; VTE-treatment dosing differs and should not be reduced by applying that AF rule. Rivaroxaban for nonvalvular AF is 20 mg PO daily with the evening meal when CrCl >50 mL/min and 15 mg daily when CrCl ≤50; avoid use at CrCl <15. Dabigatran has substantial renal clearance; labeled dosing depends on indication and CrCl. Verify current product labeling and a trusted dosing reference (Lexicomp, UpToDate, or institutional protocol), especially in AKI, dialysis, or extremes of age/weight. Pediatric dosing differs and is indication-specific.
High-Yield Pearls
In rapidly changing kidney function, a previously appropriate DOAC dose may no longer match current clearance; compare current CrCl with the patient’s baseline.
Dabigatran is the notable dialyzable DOAC; remember this when severe renal impairment and persistent drug effect coexist.
The Mimics
Uremic platelet dysfunction — mucosal or procedural bleeding with severe uremia may occur independent of DOAC concentration; attributing all bleeding to the anticoagulant misses a concurrent mechanism.
Vitamin K antagonist effect — INR is useful for warfarin but not a reliable measure of DOAC intensity; using it to exclude DOAC effect can delay reversal.
DIC — thrombocytopenia and abnormalities across coagulation studies suggest a broader consumptive process; treating only the DOAC misses the underlying emergency.
GI lesion without active major bleeding — occult or slow blood loss may not require immediate antidote; reflex reversal can expose the patient to thrombosis.
Board Question
A patient taking apixaban presents with major bleeding and acute kidney injury. The INR is normal. Which statement is most accurate?
AA normal INR excludes clinically significant apixaban effect
BKidney disease alone requires andexanet alfa
CA normal INR does not reliably exclude apixaban effect; treat major bleeding based on clinical severity and relevant drug history
DHemodialysis reliably removes apixaban
Reveal answer
Correct: C
PT/INR is not a dependable measure of apixaban activity, and reversal is driven by serious bleeding rather than renal dysfunction alone. Apixaban is not meaningfully removed by hemodialysis.
Kidney function affects DOAC selection, dosing, and bleeding risk, making renal assessment essential before prescribing or continuing anticoagulation in the ED.
A quick test of recall from prior editions. Commit to an answer before you check.
From yesterday's edition
A 28-year-old man with no medical history presents with palpitations and lightheadedness that started at rest. He is alert and talking, blood pressure 108/70. What’s the diagnosis, and the first move?
Check your answer
Idiopathic Fascicular Ventricular Tachycardia. In a stable patient, once you have confirmed VT, verapamil is first-line and often terminates it. If there is any suspicion of digoxin toxicity, give digoxin immune Fab instead; treat the unstable patient with electrical cardioversion.
From the October 6 edition
Today, three days ago: Naloxone. What’s the adult ED dose, and the contraindication you’d most regret missing?
Check your answer
0.04–0.4 mg IV titrated to respiratory rate (start low to avoid precipitated withdrawal). 2 mg IN or IM (community dosing). Infusion: start at 2/3 of the effective bolus dose per hour. Known hypersensitivity (rare).
From the September 29 edition
A malnourished patient develops weakness and ventricular ectopy after nutrition is restarted. Which electrolyte abnormality is most characteristic of refeeding syndrome? -
AHyperphosphatemia -
BHypophosphatemia -
CHypermagnesemia -
DHypercalcemia
Reveal answer
Correct · B
Insulin-driven intracellular uptake after carbohydrate reintroduction can sharply lower serum phosphate. Potassium and magnesium may also fall and contribute to cardiac or neuromuscular complications.
Journal Watch
From the FOAMed wire
Notable posts and reviews from the last week, ranked by relevance to today’s lead and source trust.
How to resolve bedside discordance in the emergency department to prevent harm. The post Missed Pediatric Shock: Vital Signs Versus Clinical Gestalt appeared first on ACEP Now .
Podcast Picks
Two for the shift
Critical Care Perspectives in Emergency Medicine2026-09-01
Brain damage and death from ischemic encephalopathy is common after cardiac arrest. Animal studies and limited observational studies suggest that high oxygen exposure after ROSC may result in neuronal death. As such, it is hypothesized that limiting oxygen exposure (conservative oxygen) many attenuate reperfusion injury and improve outcomes. At present,...
Source
Critical Care Perspectives in Emergency Medicine
Published
2026-09-01
Host
Critical Care Perspectives in Emergency Medicine, Critical Care Perspectives in Emergency Medicine
Ilene, Paul Aronson, and Nate Kuppermann dive deep into the latest 60-90 day pediatric fever guidelines, Swami and Evie get into the neurocrit hodgepodge, while Gita and Neha chat about thoracolumbar fractures. Mel...
Annals Journal Watch
From the specialty flagship
One recent paper from Annals of Emergency Medicine worth knowing on shift, chosen for practice impact — independent of today’s topics.
Lankaputhra M, Bishop A, Wijaya J, et al. · PMID 42841835
An analysis of final diagnoses and outcomes after paramedic-suspected STEMI examines what a prehospital STEMI alert ultimately represents. Residents must act quickly on these alerts without overlooking patients whose urgent diagnosis is something else.
Bottom line → Review the field ECG and clinical picture promptly, pursuing reperfusion when indicated while checking for dangerous alternative diagnoses.
UMEM Pearl
Matched to today’s topics
A clinical pearl from the University of Maryland EM group’s Educational Pearls, tied to today’s differential.
When a child with cancer develops neutropenic septic shock, PRoMPT BOLUS found no significant difference in kidney events or mortality between balanced crystalloids and normal saline.
The PRoMPT BOLUS trial (Pragmatic Pediatric Trial of Balanced versus Normal Saline Fluid in Sepsis) is the largest randomized controlled trial to date comparing balanced crystalloids to 0.9% normal saline in children with septic shock. The primary outcome showed no significant difference in major adverse kidney events at 30 days between the two groups. The secondary outcome showed no significant difference in 30 or 90 day mortality.
Critical Care Corner
Matched to today’s topics
A critical-care reference from LITFL’s Critical Care Compendium, tied to today’s differential.
In pediatric tumor lysis syndrome, acute kidney injury can turn electrolyte abnormalities into a need for renal support.
AKI is the entire spectrum of disease (mild -> severe), and can be defined as an abrupt (1 to 7 days) and sustained (more than 24 hours) decrease in kidney function. Mortality of critically patients with acute renal failure is high (50%–60%)
Pharmacology Corner
Two drugs for the shift
One antimicrobial and one other ED workhorse — selected daily, with sources and last-reviewed dates so every dose is cross-checkable.
Antimicrobial of the Day
Clindamycin
Lincosamide antibiotic; toxin-suppressing protein synthesis inhibitor
Indication
Adjunctive toxin suppression in necrotizing fasciitis or streptococcal toxic shock; anaerobic and gram-positive coverage in selected dental, skin, and soft tissue infections; alternative in some beta-lactam allergy scenarios.
What’s your dose? — reveal dosing & cautions
ED Dose
600–900 mg IV q8h for severe infection. 300–450 mg PO q6–8h for outpatient SSTI/dental infections when appropriate.
Renal Adjustment
No renal dose adjustment.
Contraindications
Known clindamycin allergy; history of severe C. difficile is a major caution.
Interactions
Neuromuscular blockers may be potentiated; erythromycin antagonism possible in vitro.
Monitoring
Diarrhea/C. difficile risk, LFTs and CBC with prolonged courses, local resistance patterns for MRSA.
ED Pearl
In suspected nec fasc or streptococcal toxic shock, clindamycin is not there for coverage breadth — it is there to suppress toxin production while definitive source control happens.
ED Pearl
Nicardipine is for controlled descent, not BP free-fall — set a disease-specific target and titrate, especially in brain bleeds and ischemic stroke.
Regular narrow-complex tachycardia without clear P waves is usually AVNRT or AVRT at the bedside — stability determines the first move.
The Tracing
A 28-year-old patient has sudden-onset palpitations while at rest. The ECG shows a regular narrow-complex tachycardia at 196 bpm. P waves are not clearly visible, and the QRS complexes are narrow and identical. The patient is anxious but normotensive.
P waves absent, retrograde, buried in QRS, or visible just after QRS depending on mechanism
QRS usually narrow unless aberrancy or pre-existing bundle branch block is present
Onset and termination are often abrupt
Includes AVNRT, orthodromic AVRT, atrial tachycardia, and other supraventricular mechanisms
Pearls
Modified Valsalva is a real treatment, not a placebo, and should be done correctly before medication when stable.
Adenosine is diagnostic and therapeutic for AV-node-dependent SVT, but warn the patient before giving it.
Capture a 12-lead before and after conversion if possible; baseline delta waves change the future plan.
Pitfalls
Do not use adenosine casually in irregular wide-complex tachycardia.
Do not miss sinus tachycardia from shock, sepsis, PE, or withdrawal; sinus tach usually has visible P waves and a clinical driver.
Do not discharge recurrent SVT without considering WPW, triggers, and follow-up.
At the Bedside
If unstable, synchronized cardioversion. If stable regular narrow SVT, use modified Valsalva then adenosine per protocol, obtain post-conversion ECG, and plan follow-up/disposition based on recurrence and risk.
For educational use only. Verify ECG interpretation against the LITFL entry and your institution’s practice before clinical decision-making.
Case of the Day
From the lead · Pediatric Oncologic Emergencies - Complications of Known Malignancy
Self-Examination
Test Your Understanding
A 9-year-old receiving chemotherapy has a temperature of 38.5°C, a central venous catheter, and stable vital signs. Which is the best next step?
AWait for the absolute neutrophil count before treating
BGive IV cefepime promptly after obtaining cultures if this does not delay treatment
CAdd vancomycin routinely to cefepime for every febrile neutropenic child
DDischarge if the child appears well and has no line-site redness
Reveal answer
Correct answer · B
Febrile neutropenia warrants prompt antipseudomonal antibiotics; treatment should not wait for the ANC or culture results. Vancomycin is reserved for specific clinical indications, not used routinely.
Study Pace4 topics today; Issue 87 of 94 — Hematology and Oncology (Week 48)Deadline · June 1, 2026